HCPCS Level II code G0460 denotes the use of autologous platelet-rich plasma (PRP) or other blood-derived products for treatment of non-diabetic chronic wounds and ulcers, encompassing phlebotomy, preparation, administration, and dressing per treatment. This code matters nationally as biologic therapies for chronic wounds are increasingly used to address complex, hard-to-heal wounds and to standardize billing for bundled preparation and application services. Clear coding affects coverage determinations, provider reimbursement, and patient access to these therapies.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service definitions, national coverage patterns and benchmark considerations where available, common billing modifiers, and policy implications relevant to outpatient wound care providers and payers. The publication outlines how G0460 is used to capture the full treatment episode per application and summarizes administrative elements that influence claims processing and payer review.

This summary aids clinicians, billing professionals, and payers in understanding the code’s scope, typical sites of service, and the kinds of documentation and coding practices that commonly accompany use of autologous blood-derived products for non-diabetic chronic wounds.